MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
HER2/EGFR in Cancer Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,303 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,303 works in the cohort · of 4,299,418page 10 of 27

Labels cover 3 of 1,303 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,303 of 1,303 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Her2 Amplification
Christopher Wixom, Elizabeth Albers, Noel Weidner
2004· article· en· Applied immunohistochemistry & molecular morphology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
26
citations
affunlabeled
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.
Alvaro Moreno‐Aspitia, Eileen Holmes, Christian Jackisch, Evandro de Azambuja, Frances Boyle, David W. Hillman +14 more
2017· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
26
citations
afffundunlabeled
Odin (ANKS1A) Modulates EGF Receptor Recycling and Stability
Jiefei Tong, Yaroslav Sydorskyy, Jonathan St‐Germain, Paul Taylor, Ming‐Sound Tsao, Michael F. Moran
2013· article· en· PLoS ONE· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
25
citations
affunlabeled
A Consortium for Analytic Standardization in Immunohistochemistry
Steven A. Bogen, David J. Dabbs, Keith D. Miller, Søren Nielsen, Suzanne Parry, Matthias Szabolcs +3 more
2022· review· en· Archives of Pathology & Laboratory Medicine· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
24
citations
affunlabeled
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
Peter Schmid, Mafalda Oliveira, Joyce O’Shaughnessy, Massimo Cristofanilli, Stephanie L. Graff, Seock-Ah Im +9 more
2025· article· en· Therapeutic Advances in Medical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
23
citations
affunlabeled
Heritable Variation of<i>ERBB2</i>and Breast Cancer Risk
Joan P. Breyer, Melinda E. Sanders, David Airey, Qiuyin Cai, Brian L. Yaspan, Peggy A. Schuyler +9 more
2009· article· en· Cancer Epidemiology Biomarkers & Prevention· Medicine
distilled prediction:candidate · noneconsensus · none
22
citations

How this was built: Screen · Findings · About